PRQR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PRQR is not a good buy right now. The trend remains bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia proprietary buy signals today; with pre-market down -5% and price sitting just above near-term support (~1.596), the risk/reward is unfavorable for an impatient entry.
Trend is still down: moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), implying the broader downtrend remains intact. Momentum is trying to stabilize but not convincingly: MACD histogram is slightly positive (0.000568) yet 'positively contracting,' suggesting weakening upside momentum rather than acceleration. RSI(6) at ~30.38 is near oversold/low-neutral, which can support a bounce, but it is not a strong reversal signal by itself. Key levels: price 1.605 is just above S1 1.596; a clean breakdown risks a move toward S2 1.545. Overhead resistance starts at the pivot 1.678, then 1.76 and 1.811—meaning upside is capped unless it reclaims ~1.678 with strength. Intellectia Proprietary Trading Signals: - AI Stock Picker: no signal on given stock today. - SwingMax: No signal on given stock recently.
No news in the past week (no fresh negative headlines). Options market is heavily call-biased, suggesting some traders are positioned for upside. Losses improved YoY in the latest reported quarter (net loss narrowed), which can support risk-on sentiment if the company shows continued cost control.
while pre-market shows -5% weakness, increasing the odds of a support break. Financially, revenue declined sharply YoY in the latest quarter, signaling weak top-line momentum. Extremely high implied volatility suggests event-driven uncertainty and unstable price action rather than a clean trend entry.
Latest quarter: 2025/Q3. Revenue fell to 2.915M (-26.78% YoY), indicating contracting top-line performance. Net income improved to -11.006M (loss narrowed by 35.74% YoY), showing better cost control or one-time effects. EPS was -0.10 (flat YoY). Gross margin reported at 100% (flat), which can occur in biotech/royalty or low-COGS revenue mixes, but the key takeaway is: profitability is still negative and growth is not currently improving on revenue.
No analyst rating/price target change data was provided, so a recent trend summary cannot be verified from the dataset. Wall Street-style pros would center on optionality from pipeline/catalysts and improving loss profile; cons would focus on shrinking revenue, ongoing net losses, and a still-bearish chart that lacks confirmation of a sustained reversal.
